• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by PLUS THERAPEUTICS Inc.

    5/1/25 10:06:06 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care
    Get the next $PSTV alert in real time by email
    DEFA14A 1 pstv-20250501.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the Securities

    Exchange Act of 1934

     

     

     

     

     

     

     

     

     

     

     

     

    Filed by the Registrant x

    Filed by a party other than the Registrant ¨

    Check the appropriate box:

    ¨ Preliminary Proxy Statement

    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ¨ Definitive Proxy Statement

    x Definitive Additional Materials

    ¨ Soliciting Material Pursuant to §240.14a-12

     

     

     

     

     

     

     

     

     

     

     

     

    img219968591_0.jpg

    PLUS THERAPEUTICS, INC.

     

     

     

     

     

     

     

     

     

     

     

     

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

    x No fee required.

    ¨ Fee paid previously with preliminary materials.

    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


     

    YOUR VOTE IS VERY IMPORTANT!
    PLEASE VOTE TODAY

     

    May 1, 2025

     

    Dear Stockholder,

     

    We are contacting you to stress the importance of voting your shares in connection with Plus Therapeutics, Inc’s special meeting of stockholders, to be held completely virtually on May 2, 2025, commencing at 9:00 a.m. Eastern Time (the “Special Meeting”). We would like to remind you to vote your shares. Your vote is very important!

     

    Stockholders are being asked to vote on the following important proposals:

     

    •
    Proposal 1: To grant discretionary authority to our Board of Directors to (i) amend our Certificate of Incorporation, as amended (the “Certificate of Incorporation”) to combine outstanding shares of our common stock, par value $0.001 per share (the “Common Stock”), into a lesser number of outstanding shares, or a “reverse stock split,” at a specific ratio within a range of one-for-twenty five (1-for-25) to a maximum of a one-for-two hundred fifty (1-for-250), with the exact ratio to be determined by our Board in its sole discretion; and (ii) effect the reverse stock split, if at all, within twelve (12) months of the date the proposal is approved by stockholders (the “Reverse Stock Split Proposal”).

     

    •
    Proposal 2: To authorize, for purposes of complying with Listing Rule 5635(d) of The Nasdaq Stock Market LLC (“Nasdaq”), the issuance of 28,042,138 Series A Warrants (as defined below) and 28,042,138 Series B Warrants, the issuance of shares of Common Stock that as a result of certain adjustment provisions set forth in the applicable warrants and assumptions described in the proxy statement distributed on April 10, 2025 (the “Proxy Statement”), could become exercisable for up to 280,421,380 shares of Common Stock in the case of the Series A Warrants and up to 1,261,896,210 shares of Common Stock in the case of the Series B Warrants (in each case subject to the potential for further adjustments), and certain provisions of the Series A Warrants and Series B Warrants, issued in connection with an offering and sale of securities in a private placement of the Company that was consummated on March 4, 2025 (the “Issuance Proposal”).

     

    •
    Proposal 3: To amend the Certificate of Incorporation to increase the authorized shares of Common Stock from 100,000,000 shares to 2,000,000,000 shares (the “Authorized Common Stock Increase Proposal”).

     

    •
    Proposal 4: To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the extension of the term of the Company’s May 2024 Warrants (as defined in the Proxy Statement) (the “Warrant Amendment Proposal”).

     

    •
    Proposal 5: To approve one or more adjournments of the Special Meeting, if necessary or appropriate, to solicit additional proxies in favor of the Reverse Stock Split Proposal, the Issuance Proposal, the Authorized Common Stock Increase Proposal and the Warrant Amendment Proposal, if there are not sufficient votes at the Special Meeting to approve and adopt the Reverse Stock Split Proposal, the Issuance Proposal, the Authorized Common Stock Increase Proposal or the Warrant Amendment Proposal (the “Adjournment Proposal”).

     

    Your vote is extremely important no matter how many shares you hold. Your Board of Directors unanimously recommends that stockholders vote FOR each of these proposals.

     

    If the shares you own are held in “street name” by a bank, broker or other nominee record holder (collectively, “brokerage firms”), your brokerage firm, as the record holder of your shares, is required to vote your shares according to your instructions. In order to vote your shares, you will need to follow the directions your brokerage firm provides you. Many brokerage firms also offer the option of voting over the Internet or by telephone, instructions for which, if available, would be provided by your brokerage firm on the voting instruction form that it delivers to you. Because most brokerage firms are member organizations of the New York Stock Exchange (“NYSE”), the rules of the NYSE govern how your brokerage firm would be permitted to vote your shares in the

     


     

    absence of instruction from you. Under the current rules of the NYSE, if you do not give instructions to your brokerage firm, it will still be able to vote your shares with respect to certain “discretionary” items, but will not be allowed to vote your shares with respect to certain “non-discretionary” items. We now expect that the Reverse Stock Split Proposal, Authorized Common Stock Increase Proposal and Adjournment Proposal will be considered to be discretionary items under the NYSE rules, and your brokerage firm will be able to vote your shares with respect to such proposals even if it does not receive instructions from you, so long as it holds your shares in its name, in which case those shares will not be considered broker non-votes. Information on how to vote is at the bottom of this message.

     

    For more information on the Special Meeting, see our Proxy Statement, available on our website at https://ir.plustherapeutics.com/reports-filings/sec-filings.

     

    On behalf of the Board of Directors, thank you for your continued support of Plus Therapeutics, Inc.

     

    Sincerely,

     

    /s/ Marc H. Hedrick

     

    Marc H. Hedrick

    President & Chief Executive Officer

     

     

    Your vote is important. Even if you plan to attend the Special Meeting, please vote as soon as possible using one of the following options:

     

     

     

     

    TIME IS SHORT-PLEASE VOTE TODAY!

     

    You can vote your shares online or by phone.

    Please use the control number found on your previously received proxy card and visit

    www.proxyvote.com to submit your instructions online, or

    if you received your original proxy statement by email, you may simply click
    the “VOTE NOW” button in the email.

     

    To vote by phone, call the phone number listed on your proxy card or voting instruction form.



     

     

     

     

     


    Get the next $PSTV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PSTV

    DatePrice TargetRatingAnalyst
    2/3/2026$2.00Buy
    Lake Street
    9/3/2025$5.00Hold → Buy
    D. Boral Capital
    3/17/2025$9.00Buy
    D. Boral Capital
    More analyst ratings

    $PSTV
    SEC Filings

    View All

    SEC Form 8-K filed by PLUS THERAPEUTICS Inc.

    8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    1/22/26 7:30:35 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by PLUS THERAPEUTICS Inc.

    8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    1/16/26 4:05:24 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form 424B4 filed by PLUS THERAPEUTICS Inc.

    424B4 - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    1/14/26 4:02:19 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sims Andrew John Hugh Macintyre bought $10,200 worth of shares (20,000 units at $0.51), increasing direct ownership by 42% to 68,138 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    11/5/25 8:30:03 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Director Lenk Robert P bought $53,779 worth of shares (110,000 units at $0.49), increasing direct ownership by 375% to 139,327 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    8/25/25 7:30:05 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Director Hawkins Richard J bought $5,996 worth of shares (4,000 units at $1.50), increasing direct ownership by 36% to 15,188 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    9/17/24 7:00:04 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization

    HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today provides a business update and highlights REYOBIQ clinical progress and CNSide US commercialization. "Our 2 key goals in 2026 are CNSide commercial scale-up and REYOBIQ pivotal trial readiness," said Dr. Marc H. Hedrick, President & Chief Executive of Plus Therapeutics. "Our recently completed upsized $15 million offering will fuel faster progress in these core areas of the business and extend our cash runway through 2027." Overview of anticipated

    1/22/26 7:45:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

    HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, January 22, 2026 before the market open. Plus Therapeutics' management team will then host a conference call and webcast at 9:00 a.m. ET to discuss and provide additional details. Webcast and Conference Call Date/Time:Thursday, January 22, 2026 @ 9:00 AM ETWebcast:https://event.choruscall.com/mediaframe/webcast.html?webcastid=x5QZCyIkParticipant Dial-in:1-888-349-0106   Please di

    1/21/26 4:15:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

    HOUSTON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces the pricing of its underwritten public offering of 39,473,684 units, with each unit consisting of one share of common stock and one warrant (the "Warrants"). Each unit is being sold to the public at a price of $0.38 per unit. The gross proceeds to the Company from this offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Each Warrant will be im

    1/14/26 8:00:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Hedrick Marc H converted options into 159,681 shares, increasing direct ownership by 89% to 339,787 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    1/2/26 4:30:06 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Sims Andrew John Hugh Macintyre converted options into 38,323 shares, increasing direct ownership by 56% to 106,461 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    1/2/26 4:30:04 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Sims Andrew John Hugh Macintyre bought $10,200 worth of shares (20,000 units at $0.51), increasing direct ownership by 42% to 68,138 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    11/5/25 8:30:03 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Plus Therapeutics with a new price target

    Lake Street initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $2.00

    2/3/26 8:52:26 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics upgraded by D. Boral Capital with a new price target

    D. Boral Capital upgraded Plus Therapeutics from Hold to Buy and set a new price target of $5.00

    9/3/25 8:18:22 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    D. Boral Capital initiated coverage on Plus Therapeutics with a new price target

    D. Boral Capital initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $9.00

    3/17/25 7:41:57 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Leadership Updates

    Live Leadership Updates

    View All

    Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

    Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations HOUSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces continued operational execution and commercial progress in the launch of its wholly owned subsidiary, CNSide Diagnostic LLC's, Cerebrospinal Fluid (CSF) Tumor Cell Enumeration laboratory developed test (LDT). Recent accomplishments include expansion of the CNSide manufacturing footprint,

    10/21/25 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

    HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the appointment of Kyle Guse, J.D., M.B.A. to the Company's Board of Directors where he will serve as chair of the Audit Committee and on the Compensation Committee. "Kyle's decades of financial, transactional and operational experience in our industry will make an immediate and positive impact to Plus' board of directors," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Furthermore, in his

    4/23/25 8:00:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

    AUSTIN, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the appointment of Michael Rosol, Ph.D., as Chief Development Officer. Dr. Rosol will lead the company's clinical, pre-clinical, and biomarker development activities. "Plus is at an inflection point in our clinical development as we move from mid-stage to pivotal trials next year," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Mike's background in oncology and radiotherapeutic

    2/20/25 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PLUS THERAPEUTICS Inc.

    SC 13G - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

    6/5/24 7:26:01 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

    SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

    2/13/23 3:25:03 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

    SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

    2/11/22 7:53:23 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $PSTV
    Financials

    Live finance-specific insights

    View All

    Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization

    HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today provides a business update and highlights REYOBIQ clinical progress and CNSide US commercialization. "Our 2 key goals in 2026 are CNSide commercial scale-up and REYOBIQ pivotal trial readiness," said Dr. Marc H. Hedrick, President & Chief Executive of Plus Therapeutics. "Our recently completed upsized $15 million offering will fuel faster progress in these core areas of the business and extend our cash runway through 2027." Overview of anticipated

    1/22/26 7:45:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

    HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, January 22, 2026 before the market open. Plus Therapeutics' management team will then host a conference call and webcast at 9:00 a.m. ET to discuss and provide additional details. Webcast and Conference Call Date/Time:Thursday, January 22, 2026 @ 9:00 AM ETWebcast:https://event.choruscall.com/mediaframe/webcast.html?webcastid=x5QZCyIkParticipant Dial-in:1-888-349-0106   Please di

    1/21/26 4:15:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights

    US market introduction of the CNSide® CSF diagnostics platform, with first national coverage agreement with UnitedHealthcare Presented positive RESPECT-LM Ph1 clinical trial results HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the third quarter ended September 30, 2025 and provides an overview of recent and upcoming business highlights. "Our team continues to execute solidly across the three most important business verticals: diagnost

    10/30/25 4:15:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care